Chercheur(e)

Dr Sébastien Bonnet

Pneumologie

A2118

sebastien.bonnet@criucpq.ulaval.ca

Domaine de recherche

Origine moléculaire et épigénétique des maladies vasculaire, approche translationnelle molécule-animal-humain, rôle des mitochondries en HTAP, pathologie métabolique en HTAP, régulation des gênes en HTAP.

Description des travaux

Dr Bonnet, professeur agrégé à la faculté de médecine à l'Université Laval, fellow de American Heart association et chercheur au centre de recherche de l'IUCPQ, poursuit ses travaux de recherche dans le domaine cardiovasculaire.
Les travaux du Dr Bonnet ont conduit à la découverte du mécanisme qui provoque l'hypertension artérielle pulmonaire. Son équipe a également repéré deux substances susceptibles de traiter efficacement cette maladie.
Le Dr Bonnet, en collaboration avec Dr Steeve Provencher, a fondé et codirige le Groupe de recherche en hypertension pulmonaire.
Le groupe du Dr Bonnet utilise une approche multidisciplinaire et translationelle (du gène a la population) afin d'étudier les mécanismes moléculaires et cellulaires impliqués dans le développement des processus de remodelage vasculaire (HTAP et coronaire) et bronchique. Ces travaux ont permis l'identification de nouveaux marqueurs de risque, améliorant ainsi l'identification et la prise en charge des individus souffrant HTAP.
Ses travaux ont aussi permis d'identifier de nouvelles cibles thérapeutiques comme Pim-1, miR-204 ou encore PARP-1 dans HTAP. Par ailleurs, de nombreux travaux conduits dans le laboratoire du Dr Bonnet visent à évaluer l'impact de ces cibles dans les maladies coronaires qui possèdent de nombreuses similitudes avec HTAP.
La création, par les Drs Bonnet et Provencher, du groupe de recherche en hypertension pulmonaire, offre de nouvelles perspectives de recherche en HTAP. En effet l'association de la recherche fondamentale et pré-clinique du Dr Bonnet à la recherche clinique du Dr Provencher permet dès à présent la réalisation de projets de recherche du laboratoire au lit du malade ce qui accélérera sans aucun doute la découverte de nouvelles thérapies.

Prix et distinctions

2014 : Prix Louise Rousselle-Trottier décerné par la Fondation des maladies du coeur et de l’AVC - Québec pour son étude intitulée « Role for DNA damage signalling in Pulmonary Hypertension ». Ce prix d’excellence est décerné au chercheur qui a atteint la plus haute note d’évaluation dans le cadre d’un projet de recherche sur l’hypertension.
2013 : Prix « Jonathan Ballon » de la Fondation des maladies du coeur - Québec, prix d’excellence pour « Role of miRNAs in pulmonary hypertension ».
2012 : En nomination pour le Springer Junior Investigator Award du North American Vascular Biology Organization. (NAVBO)
2011 : Membre honoré et distingué de l’association d’hypertension pulmonaire.
2011 : Meilleur résumé de l’American Heart Association.
2011 : Nommé fellow de l’American Heart Association.
2011 : Prix du jeune chercheur décerné par la Société Québécoise d’Hypertension Artérielle. (SQHA)
2010 : Meilleur chercheur canadien du mois de décembre selon le CHR. (Canadian for Health Research)
2010 : Prix du jeune chercheur par Hypertension Canada.
2010 : Prix du jeune chercheur par Canadian Cardiovascular Society.
2009 : Prix du Cardiovascular Health Network (CHN) - Pfizer Canada, Grant for the Future.
2009 : Prix du meilleur résumé par l’American Heart Association.
2008 : Bourse salariale pour nouveau chercheur de la Fondation des maladies du coeur du Canada.
2006 : Prix Paul Mann pour la recherche translationelle.
2005 : Prix Fraser Mustard des Instituts de Recherche en Santé du Canada. (IRSC)
2004 : Prix pour jeune chercheur Courmand & Comoroe de l’American Heart Association.

Publications

150

Trier par année :

Barrier M, Meloche J, Jacob MH, Courboulin A, Provencher S, Bonnet S. Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.. Cell Mol Life Sci 2012; 69(17):2805-31.
Courboulin A, Barrier M, Perreault T, Bonnet P, Tremblay VL, Paulin R, Tremblay E, Lambert C, Jacob MH, Bonnet SN, Provencher S, Bonnet S. Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH.. Eur Respir J 2012; 40(3):618-29.
Sutendra G, Dromparis P, Wright P, Bonnet S, Haromy A, Hao Z, McMurtry MS, Michalak M, Vance JE, Sessa WC, Michelakis ED. The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension.. Sci Transl Med 2011; 3(88):88ra55.
Meloche J, Paulin R, Courboulin A, Lambert C, Barrier M, Bonnet P, Bisserier M, Roy M, Sussman MA, Agharazii M, Bonnet S. RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes.. Arterioscler Thromb Vasc Biol 2011; 31(9):2114-24.
Paulin R, Courboulin A, Barrier M, Bonnet S. From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension.. J Mol Med (Berl) 2011; 89(11):1089-101.
Dumas de la Roque E, Storme L, Mauriat P, Bonnet S. [Pulmonary hypertension in pediatric and neonatal intensive care unit. Part I: Physiopathology].. Arch Pediatr 2011; 18(1):68-75.
Paulin R, Courboulin A, Meloche J, Mainguy V, Dumas de la Roque E, Saksouk N, Côté J, Provencher S, Sussman MA, Bonnet S. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension.. Circulation 2011; 123(11):1205-15.
Courboulin A, Paulin R, Giguère NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Côté J, Simard MJ, Bonnet S. Role for miR-204 in human pulmonary arterial hypertension.. J Exp Med 2011; 208(3):535-48.
Sutendra G, Dromparis P, Bonnet S, Haromy A, McMurtry MS, Bleackley RC, Michelakis ED. Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNF? contributes to the pathogenesis of pulmonary arterial hypertension.. J Mol Med (Berl) 2011; 89(8):771-83.
Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A, Bonnet S. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension.. Am J Physiol Heart Circ Physiol 2011; 301(5):H1798-809.
Paulin R, Barrier M, Bonnet S. Therapeutics for pulmonary arterial hypertension: do gene therapies have translational values?. Clin Investig (Lond) 2011; 1(3):363-6.
Dumas de la Roque E, Storme L, Mauriat P, Bonnet S. [Pulmonary hypertension in pediatric and neonatal intensive care unit. Part II: diagnosis and treatment].. Arch Pediatr 2011; 18(2):195-203.
Courboulin A, Tremblay VL, Barrier M, Meloche J, Jacob MH, Chapolard M, Bisserier M, Paulin R, Lambert C, Provencher S, Bonnet S.. Krüppel-like Factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension.. Respir Res 2011; 12(1):128.
Paulin R, Bonnet S. Dehydroepiandrosterone, Over-studied but Under-used in the Treatment of Vascular Remodeling Diseases.. J Steroids Horm Sci 2011; 0(0):001.
Mainguy V, Malenfant S, Neyron AS, Bonnet S, Maltais F, Saey D, Provencher S. Repeatability and responsiveness of exercise tests in pulmonary arterial hypertension.. Eur Respir J 2013; 42(2):425-34.
Paulin R, Meloche J, Bonnet S. STAT3 signaling in Pulmonary Arterial Hypertension. JAK-STAT journal 2012; 0(0):1-11.
Dromparis P, Paulin R, Sutendra G, Qi AC, Bonnet S, Michelakis ED.. Uncoupling protein 2 deficiency mimics the effects of hypoxia and endoplasmic reticulum stress on mitochondria and triggers pseudohypoxic pulmonary vascular remodeling and pulmonary hypertension.. Circ Res 2013; 113(2):126-36.
Paulin R, Meloche J, Courboulin A, Lambert C, Haromy A, Courchesne A, Bonnet P, Provencher S, Michelakis ED, Bonnet S.. Targeting cell motility in pulmonary arterial hypertension.. Eur Respir J 2014; 43(2):531-44.
Malenfant S, Neyron AS, Potus F, Provencher S, Bonnet S. Signal transduction pathways in the development of pulmonary arterial hypertension.. Pulm Circ 2013; 3(2):278-93.
Malenfant S, Margaillan G, Loehr JE, Bonnet S, Provencher S. The emergence of new therapeutic targets in pulmonary arterial hypertension: from now to the near future.. Expert Rev Respir Med 2013; 7(1):43-55.
Meloche J, Courchesne A, Barrier M, Carter S, Bisserier M, Paulin R, Lauzon-Joset JF, Breuils-Bonnet S, Tremblay E, Biardel S, Racine C, Courture C, Bonnet P, Majka SM, Deshaies Y, Picard F, Provencher S, Bonnet S. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.. J Am Heart Assoc 2013; 2(1):e005157.
Meloche J, Paulin R, Provencher S, Bonnet S. Therapeutic potential of microRNA modulation in pulmonary arterial hypertension.. Curr Vasc Pharmacol 2013; 0(0):Epub.
Renard S, Paulin R, Breuils-Bonnet S, Simard S, Pibarot P, Bonnet S, Provencher S. Pim-1: a new biomarker in pulmonary arterial hypertension.. Pulm Circ 2013; 3(1):74-81.
Provencher S, Bonnet S. Pulmonary arterial hypertension research : Why does it take so long? How can I contribute?. Connect (Tor) 2012; 3(2):26-27.
Potus F, Graydon C, Provencher S, Bonnet S.. Vascular remodeling process in pulmonary arterial hypertension, with focus on miR-204 and miR-126 (2013 Grover Conference series).. Pulm Circ 2014; 4(2):175-84.
Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulos S, Graydon C, Courboulin A, Breuils-Bonnet S, Tremblay E, Couture C, Michelakis ED, Provencher S, Bonnet S. Role for DNA damage signaling in pulmonary arterial hypertension.. Circulation 2013; 0(0):Epub.
Sutendra G, Bonnet S. The iron paradigm of pulmonary arterial hypertension: Popeye knows best.. Circ Res 2015; 116(10):1636-8.
Malenfant S, Potus F, Mainguy V, Leblanc È, Malenfant M, Ribeiro F, Saey D, Maltais F, Bonnet S, Provencher S. Impaired Skeletal Muscle Oxygenation and Exercise Tolerance in Pulmonary Hypertension.. Med Sci Sports Exerc 2015; 47(11):2273-82.
Courboulin A, Kang C, Baillard O, Bonnet S, Bonnet P. Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets.. J Vis Exp 2015; 0(99):e52571.
Paulin R, Sutendra G, Gurtu V, Dromparis P, Haromy A, Provencher S, Bonnet S, Michelakis ED. A miR-208-Mef2 Axis Drives the Decompensation of Right Ventricular Function in Pulmonary Hypertension.. Circ Res 2015; 116(1):56-69.
Boucherat O, Bonnet S. NOGGIN: a new therapeutic target for PH? Focus on "Noggin Inhibits Hypoxia-Induced Proliferation by Targeting Store-operated Calcium Entry and TRPC Channels".. Am J Physiol Cell Physiol 2015; 308(11):C867-8.
Boucherat O, Potus F, Bonnet S. microRNA and Pulmonary Hypertension.. Adv Exp Med Biol 2015; 888(0):237-52.
Malenfant S, Potus F, Fournier F, Breuils-Bonnet S, Pflieger A, Bourassa S, Tremblay È, Nehmé B, Droit A, Bonnet S, Provencher S. Skeletal muscle proteomic signature and metabolic impairment in pulmonary hypertension.. J Mol Med (Berl) 2015; 93(5):573-84.
Paulin R, Dromparis P, Sutendra G, Gurtu V, Zervopoulos S, Bowers L, Haromy A, Webster L, Provencher S, Bonnet S, Michelakis ED. Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans.. Cell Metab 2014; 20(5):827-39.
Mainguy V, Malenfant S, Neyron AS, Saey D, Maltais F, Bonnet S, Provencher S. Alternatives to the six-minute walk test in pulmonary arterial hypertension.. PLoS One 2014; 9(8):e103626.
Potus F, Malenfant S, Graydon C, Mainguy V, Tremblay È, Breuils-Bonnet S, Ribeiro F, Porlier A, Maltais F, Bonnet S, Provencher S. Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension.. Am J Respir Crit Care Med 2014; 190(3):318-28.
Sharma S, Umar S, Potus F, Iorga A, Wong G, Meriwether D, Breuils-Bonnet S, Mai D, Navab K, Ross D, Navab M, Provencher S, Fogelman AM, Bonnet S, Reddy ST, Eghbali M. Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p.. Circulation 2014; 130(9):776-85.
Meloche J, Pflieger A, Vaillancourt M, Graydon C, Provencher S, Bonnet S. miRNAs in PAH: biomarker, therapeutic target or both?. Drug Discov Today 2014; 19(8):1264-9.
Rival G, Lacasse Y, Martin S, Bonnet S, Provencher S. Effect of pulmonary arterial hypertension-specific therapies on health-related quality of life: a systematic review.. Chest 2014; 146(3):686-708.
Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulos S, Graydon C, Courboulin A, Breuils-Bonnet S, Tremblay E, Couture C, Michelakis ED, Provencher S, Bonnet S. Role for DNA damage signaling in pulmonary arterial hypertension.. Circulation 2014; 129(7):786-97.
Vaillancourt M, Ruffenach G, Meloche J, Bonnet S. Adaptation and Remodelling of the Pulmonary Circulation in Pulmonary Hypertension.. Can J Cardiol 2015; 31(4):407-415.
Meloche J, Potus F, Vaillancourt M, Bourgeois A, Johnson I, Deschamps L, Chabot S, Ruffenach G, Henry S, Breuils-Bonnet S, Tremblay È, Nadeau V, Lambert C, Paradis R, Provencher S, Bonnet S. Bromodomain-Containing Protein 4: The Epigenetic Origin of Pulmonary Arterial Hypertension.. Circ Res 2015; 117(6):525-35.
Boucherat O, Chabot S, Antigny F, Perros F, Provencher S, Bonnet S. Potassium channels in pulmonary arterial hypertension.. Eur Respir J 2015; 46(4):1167-77.
Perros F, Bonnet S. Bone Morphogenetic Protein Receptor Type II and Inflammation Are Bringing Old Concepts into the New Pulmonary Arterial Hypertension World.. Am J Respir Crit Care Med 2015; 192(7):777-9.
Meloche J, Le Guen M, Potus F, Vinck J, Ranchoux B, Johnson I, Antigny F, Tremblay E, Breuils-Bonnet S, Perros F, Provencher S, Bonnet S. miR-223 reverses experimental pulmonary arterial hypertension.. Am J Physiol Cell Physiol 2015; 309(6):C363-72.
Potus F, Ruffenach G, Dahou A, Thebault C, Breuils-Bonnet S, Tremblay È, Nadeau V, Paradis R, Graydon C, Wong R, Johnson I, Paulin R, Lajoie AC, Perron J, Charbonneau E, Joubert P, Pibarot P, Michelakis ED, Provencher S, Bonnet S. Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension.. Circulation 2015; 132(10):932-43.
Antigny F, Hautefort A, Meloche J, Belacel-Ouari M, Manoury B, Rucker-Martin C, Péchoux C, Potus F, Nadeau V, Tremblay E, Ruffenach G, Bourgeois A, Dorfmüller P, Breuils-Bonnet S, Fadel E, Ranchoux B, Jourdon P, Girerd B, Montani D, Provencher S, Bonnet S, Simonneau G, Humbert M, Perros F. Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension.. Circulation 2016; 133(14):1371-85.
Lajoie AC, Lauzière G, Lega JC, Lacasse Y, Martin S, Simard S, Bonnet S, Provencher S. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis.. Lancet Respir Med 2016; 4(4):291-305.
Boucherat O, Morissette MC, Provencher S, Bonnet S, Maltais F. Bridging Lung Development with Chronic Obstructive Pulmonary Disease. Relevance of Developmental Pathways in Chronic Obstructive Pulmonary Disease Pathogenesis.. Am J Respir Crit Care Med 2016; 193(4):362-75.
Courboulin A, Ranchoux B, Cohen-Kaminsky S, Perros F, Bonnet S. MicroRNA networks in pulmonary arterial hypertension: share mechanisms with cancer?. Curr Opin Oncol 2016; 28(1):72-82.
Potus F, LeGuen M, Provencher S, Meloche J, Bonnet S.. DNA damage at the dawn of micro-RNA pathway impairment in pulmonary arterial hypertension. RNA Dis 2015; 2(4):e810.
Ruffenach G, Chabot S, Tanguay VF, Courboulin A, Boucherat O, Potus F, Meloche J, Pflieger A, Breuils-Bonnet S, Nadeau V, Paradis R, Tremblay E, Girerd B, Hautefort A, Montani D, Fadel E, Dorfmuller P, Humbert M, Perros F, Paulin R, Provencher S, Bonnet S. Role for RUNX2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension.. Am J Respir Crit Care Med 2016; 194(10):1273-85.
Bonnet S, Provencher S. Shear Stress Maladaptation in Pulmonary Arterial Hypertension. An Ageless Concept.. Am J Respir Crit Care Med 2016; 193(12):1331-2.
Boucherat O, Bonnet S, Paulin R. The HIPPO-Thesis of Pulmonary HYPERtension.. Am J Respir Crit Care Med 2016; 194(7):787-789.
Ranchoux B, Meloche J, Paulin R, Boucherat O, Provencher S, Bonnet S. DNA Damage and Pulmonary Hypertension.. Int J Mol Sci 2016; 17(6):E990.
Boucherat O, Bonnet S. MicroRNA signature of end-stage idiopathic pulmonary arterial hypertension: clinical correlations and regulation of WNT signaling.. J Mol Med (Berl) 2016; 94(8):849-51.
Bonnet S, Provencher S, Guignabert C, Perros F, Boucherat O, Schermuly RT, Hassoun PM, Rabinovitch M, Nicolls MR, Humbert M. Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension.. Am J Respir Crit Care Med 2017; 195(5):583-595.
Chun HJ, Bonnet S, Chan SY. Translational Advances in the Field of Pulmonary Hypertension. Translating MicroRNA Biology in Pulmonary Hypertension. It Will Take More Than "miR" Words.. Am J Respir Crit Care Med 2017; 195(2):167-178.
Hong Z, Chen KH, DasGupta A, Potus F, Dunham-Snary K, Bonnet S, Tian L, Fu J, Breuils-Bonnet S, Provencher S, Wu D, Mewburn J, Ormiston ML, Archer SL. MicroRNA-138 and MicroRNA-25 Down-regulate Mitochondrial Calcium Uniporter, Causing the Pulmonary Arterial Hypertension Cancer Phenotype.. Am J Respir Crit Care Med 2017; 195(4):515-529.
Paulin R, Bonnet S. Epigenetics, Inflammation and Metabolism in Right Heart Failure Associated with Pulmonary Hypertension.. Pulm Circ 2017; 7(3):572-87.
Antigny F, Ranchoux B, Nadeau V, Lau E, Bonnet S, Perros F. Corrigendum to "A Simple Method to Assess In Vivo Proliferation in Lung Vasculature with EdU: The Case of MMC-Induced PVOD in Rat".. Anal Cell Pathol (Amst) 2017; 2017(0):4697379.
Perros F, de Man FS, Bogaard HJ, Antigny F, Simonneau G, Bonnet S, Provencher S, Galiè N, Humbert M. Use of ?-Blockers in Pulmonary Hypertension.. Circ Heart Fail 2017; 10(4):e003703.
Lajoie AC, Bonnet S, Provencher S. Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges.. Pulm Circ 2017; 7(2):312-325.
Lajoie AC, Bonnet S, Provencher S. Clinical trial research in focus: improving drug development and trial design in pulmonary arterial hypertension.. Lancet Respir Med 2017; 5(7):544-546.
Boucherat O, Chabot S, Paulin R, Trinh I, Bourgeois A, Potus F, Lampron MC, Lambert C, Breuils-Bonnet S, Nadeau V, Paradis R, Goncharova EA, Provencher S, Bonnet S. HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension.. Sci Rep 2017; 7(1):4546.
Meloche J, Lampron MC, Nadeau V, Maltais M, Potus F, Lambert C, Tremblay E, Vitry G, Breuils-Bonnet S, Boucherat O, Charbonneau E, Provencher S, Paulin R, Bonnet S. Implication of Inflammation and Epigenetic Readers in Coronary Artery Remodeling in Patients With Pulmonary Arterial Hypertension. Arterioscler Thromb Vasc Biol 2017; 37(8):1513-23.
Boucherat O, Vitry G, Trinh I, Paulin R, Provencher S, Bonnet S. The cancer theory of Pulmonary Arterial Hypertension.. Pulm Circ 2017; 7(2):285-99.
Provencher S, Archer SL, Ramirez FD, Hibbert B, Paulin R, Boucherat O, Lacasse Y, Bonnet S.. Standards and Methodological Rigor in Pulmonary Arterial Hypertension Preclinical and Translational Research.. Circ Res 2018; 122(7):1021-32.
Tanguay VF, Babin C, Giardetti G, Sohier-Poirier C, Ménard-Cholette V, Ranchoux B, Ruffenach G, Montani D, Bonnet S, Provencher S. Enhanced Pulmonary Artery Radiodensity in Pulmonary Arterial Hypertension: A Sign of Early Calcification?. Am J Respir Crit Care Med 2019; 199(6):799-802.
Malenfant S, Brassard P, Paquette M, Le Blanc O, Chouinard A, Nadeau V, Allan PD, Tzeng YC, Simard S, Bonnet S, Provencher S. Compromised Cerebrovascular Regulation and Cerebral Oxygenation in Pulmonary Arterial Hypertension.. J Am Heart Assoc 2017; 6(10):e006126.
Lajoie AC, Guay CA, Lega JC, Lauzière G, Simard S, Lambert C, Lacasse Y, Bonnet S, Provencher S. Trial Duration and Risk Reduction in Combination Therapy Trials for Pulmonary Arterial Hypertension: A Systematic Review.. Chest 2018; 153(5):1142-1152.
Chechi K, Voisine P, Mathieu P, Laplante M, Bonnet S, Picard F, Joubert P, Richard D. Functional characterization of the Ucp1-associated oxidative phenotype of human epicardial adipose tissue.. Sci Rep 2017; 7(1):15566.
Boucherat O, Provencher S, Bonnet S. Therapeutic value of ASK1 inhibition in pulmonary arterial hypertension.. Am J Respir Crit Care Med 2018; 197(3):284-6.
Nadeau V, Potus F, Boucherat O, Paradis R, Tremblay E, Iglarz M, Paulin R, Bonnet S, Provencher S. Dual ET_A/ET_B blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension.. Pulm Circ 2018; 8(1):204589321774142.
Zabini D, Granton E, Hu Y, Miranda MZ, Weichelt U, Breuils Bonnet S, Bonnet S, Morrell NW, Connelly KA, Provencher S, Ghanim B, Klepetko W, Olschewski A, Kapus A, Kuebler WM. Loss of SMAD3 Promotes Vascular Remodeling in Pulmonary Arterial Hypertension via MRTF Disinhibition.. Am J Respir Crit Care Med 2018; 197(2):244-260.
Ruffenach G, Bonnet S, Rousseaux S, Khochbin S, Provencher S, Perros F. Identity crisis in pulmonary arterial hypertension.. Pulm Circ 2018; 8(1):2045893217746054.
Boucherat O, Peterlini T, Bourgeois A, Nadeau V, Breuils-Bonnet S, Boilet-Molez S, Potus F, Meloche J, Chabot S, Lambert C, Tremblay E, Chae YC, Altieri DC, Sutendra G, Michelakis ED, Paulin R, Provencher S, Bonnet S. Mitochondrial HSP90 Accumulation Promotes Vascular Remodeling in Pulmonary Arterial Hypertension.. Am J Respir Crit Care Med 2018; 198(1):90-103.
Bourgeois A, Lambert C, Habbout K, Ranchoux B, Paquet-Marceau S, Trinh I, Breuils-Bonnet S, Paradis R, Nadeau V, Paulin R, Provencher S, Bonnet S, Boucherat O. FOXM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension.. J Mol Med (Berl) 2018; 96(2):223-235.
Frump AL, Bonnet S, de Jesus Perez VA, Lahm T. Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension.. Am J Physiol Lung Cell Mol Physiol 2018; 314(3):L443-L460.
Ranchoux B, Harvey LD, Ayon RJ, Babicheva A, Bonnet S, Chan SY, Yuan JX, Perez VJ. Endothelial dysfunction in pulmonary arterial hypertension: an evolving landscape (2017 Grover Conference Series).. Pulm Circ 2018; 8(1):204589321775291.
Chen KH, Dasgupta A, Lin J, Potus F, Bonnet S, Iremonger J, Fu J, Mewburn J, Wu D, Dunham-Snary K, Theilmann AL, Jing ZC, Hindmarch C, Ormiston ML, Lawrie A, Archer SL. Epigenetic Dysregulation of the Dynamin-Related Protein 1 Binding Partners MiD49 and MiD51 Increases Mitotic Mitochondrial Fission and Promotes Pulmonary Arterial Hypertension: Mechanistic and Therapeutic Implications.. Circulation 2018; 138(3):287-304.
Bonnet S, Boucherat O. The ROS controversy in hypoxic pulmonary hypertension revisited.. Eur Respir J 2018; 51(3):1800276.
Kuebler WM, Bonnet S, Tabuchi A. Inflammation and autoimmunity in pulmonary hypertension: is there a role for endothelial adhesion molecules? (2017 Grover Conference Series).. Pulm Circ 2018; 8(2):2045893218757596.
Adão R, Mendes-Ferreira P, Santos-Ribeiro D, Maia-Rocha C, Pimentel L, Pinto C, Mulvaney EP, Reid HM, Kinsella BT, Potus F, Breuils-Bonnet S, Rademaker MT, Provencher S, Bonnet S, Leite-Moreira A, Brás-Silva C.. Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension.. Cardiovasc Res 2018; 114(8):1165-1177.
Bourgeois A, Omura J, Habbout K, Bonnet S, Boucherat O. Pulmonary arterial hypertension: New pathophysiological insights and emerging therapeutic targets.. Int J Biochem Cell Biol 2018; 104(0):9-13.
Agarwal S, Spiekerkoetter E, Austin ED, de Jesus Perez V, Dezfulian C, Maron BA, Ryan JJ, Starks MA, Yu PB, Bonnet S, Perman SM.. Career Development of Young Physician-Scientists in the Cardiovascular Sciences: Perspective and Advice From the Early Career Committee of the Cardiopulmonary, Critical Care, and Resuscitation Council of the American Heart Association.. Circ Res 2018; 122(10):1330-3.
Lajoie AC, Bonnet S, Lacasse Y, Provencher S.. Interpreting risk reduction in clinical trials for pulmonary arterial hypertension.. Eur Respir Rev 2018; 27(148):180020.
Guay CA, Morin-Thibault LV, Bonnet S, Lacasse Y, Lambert C, Lega JC, Provencher S. Pulmonary hypertension-targeted therapies in heart failure: A systematic review and meta-analysis.. PLoS One 2018; 13(10):e0204610.
Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, Olschewski AJ, Pullamsetti SS, Schermuly RT, Stenmark KR, Rabinovitch M.. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives.. Eur Respir J 2019; 53(1):1801887.
Omura J, Bonnet S, Kutty S.. Right Ventricular and Pulmonary Vascular Changes in Pulmonary Hypertension Associated With Left Heart Disease.. Am J Physiol Heart Circ Physiol 2019; 316(5):H1144-H1145.
Bonnet S, Paulin R, Provencher S, Boucherat O. Small SeP or Giant Leap for Pulmonary Hypertension Research?. Circulation 2018; 138(6):624-626.
Mai V, Guay CA, Perreault L, Bonnet S, Bertoletti L, Lacasse Y, Jardel S, Lega JC, Provencher S. Extended Anticoagulation for VTE: A Systematic Review and Meta-Analysis.. Chest 2019; 155(6):1199-1216.
Bourgeois A, Bonnet S, Breuils-Bonnet S, Habbout K, Paradis R, Tremblay E, Lampron MC, Orcholski ME, Potus F, Bertero T, Peterlini T, Chan SY, Norris KA, Paulin R, Provencher S, Boucherat O. Inhibition of CHK 1 (Checkpoint Kinase 1) Elicits Therapeutic Effects in Pulmonary Arterial Hypertension.. Arterioscler Thromb Vasc Biol 2019; 39(8):1667-1681.
Kurakula K, Boucherat O, Van der Feen DE, Bogaard HJ, Kulikowski E, Bartelds B, Provencher S, Berger RMF, Bonnet S, Goumans MJ. Reply to Piquereau and Perros and to Pullamsetti and de Jesus Perez.. Am J Respir Crit Care Med 2019; 200(9):1190-1191.
Van der Feen DE, Kurakula K, Tremblay E, Boucherat O, Bossers GPL, Szulcek R, Bourgeois A, Lampron MC, Habbout K, Martineau S, Paulin R, Kulikowski E, Jahagirdar R, Schalij I, Bogaard HJ, Bartelds B, Provencher S, Berger RMF, Bonnet S, Goumans MJ. Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension.. Am J Respir Crit Care Med 2019; 200(7):910-920.
Bonnet S, Boucherat O, Provencher S, Paulin R. Early Evidence for the Role of lncRNA TUG1 in Vascular Remodelling in Pulmonary Hypertension.. Can J Cardiol 2019; 35(11):1433-1434.
Boucherat O, Paulin R, Provencher S, Bonnet S. New Insights Into HIMF (Hypoxia-Induced Mitogenic Factor)-Mediated Signaling Pathways in Pulmonary Hypertension.. Arterioscler Thromb Vasc Biol 2019; 39(12):2451-2453.
Ranchoux B, Nadeau V, Bourgeois A, Provencher S, Tremblay É, Omura J, Coté N, Abu-Alhayja'a R, Dumais V, Nachbar RT, Tastet L, Dahou A, Breuils-Bonnet S, Marette A, Pibarot P, Dupuis J, Paulin R, Boucherat O, Archer SL, Bonnet S, Potus F.. Metabolic Syndrome Exacerbates Pulmonary Hypertension due to Left Heart Disease.. Circ Res 2019; 125(4):449-466.
Nadeau V, Bonnet S, Paulin R. Letter by Nadeau et al Regarding Article, "Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension".. Circulation 2019; 140(7):e286-e287.
Bonnet S, Paulin R. Involvement of PFKFB3 in Pulmonary Arterial Hypertension Pathogenesis. Is It All about Glycolysis?. Am J Respir Crit Care Med 2019; 200(5):532-534.
Chelladurai P, Boucherat O, Stenmark K, Kracht M, Seeger W, Bauer UM, Bonnet S, Pullamsetti SS. Targeting histone acetylation in pulmonary hypertension and right ventricular hypertrophy.. Br J Pharmacol 2021; 178(1):54-71.
Bonnet S, Boucherat O, Paulin R, Wu D, Hindmarch CCT, Archer SL, Song R, Moore JB, Provencher S, Zhang L, Uchida S. Clinical Value of Non-Coding RNAs in Cardiovascular, Pulmonary, and Muscle Diseases.. Am J Physiol Cell Physiol 2020; 318(1):C1-C28.
Provencher S, Boucherat O, Berger RMF, Goumans MJ, Bonnet S. Reply to Ning et al.: More Insights into the Association between RVX-208 and Pulmonary Arterial Hypertension.. Am J Respir Crit Care Med 2020; 201(3):389-391.
Lampron MC, Vitry G, Nadeau V, Grobs Y, Paradis R, Samson N, Tremblay È, Boucherat O, Meloche J, Bonnet S, Provencher S, Potus F, Paulin R. PIM1 (Moloney Murine Leukemia Provirus Integration Site) Inhibition Decreases the Nonhomologous End-Joining DNA Damage Repair Signaling Pathway in Pulmonary Hypertension.. Arterioscler Thromb Vasc Biol 2020; 40(3):783-801.
Vitry G, Paulin R, Grobs Y, Lampron MC, Shimauchi T, Lemay SE, Tremblay E, Habbout K, Awada C, Bourgeois A, Nadeau V, Paradis R, Breuils-Bonnet S, Roux-Dalvai F, Orcholski M, Potus F, Provencher S, Boucherat O, Bonnet S. Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in PAH.. Am J Respir Crit Care Med 2021; 203(5):614-627.
Provencher S, Boucherat O, Potus F, Bonnet S. Pulmonary hypertension thresholds: time to lower further?. Lancet Respir Med 2020; 8(9):834-836.
Boucherat O, Austin ED, Bonnet S. Revisiting the Role for HIF Stabilizers in Bronchopulmonary Dysplasia.. Am J Respir Crit Care Med 2020; 202(8):1075-1077.
Omura J, Habbout K, Shimauchi T, Wu WH, Breuils-Bonnet S, Tremblay E, Martineau S, Nadeau V, Gagnon K, Mazoyer F, Perron J, Potus F, Lin JH, Zafar H, Kiely DG, Lawrie A, Archer SL, Paulin R, Provencher S, Boucherat O, Bonnet S. Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension.. Circulation 2020; 142(15):1464-1484.
Provencher S, Potus F, Bonnet S. COVID-19 and the pulmonary vasculature.. Pulm Circ 2020; 10(3):2045894020933088.
Potus F, Mai V, Lebret M, Malenfant S, Breton-Gagnon E, Lajoie AC, Boucherat O, Bonnet S, Provencher S. Novel insights on the pulmonary vascular consequences of COVID-19.. Am J Physiol Lung Cell Mol Physiol 2020; 319(2):L277-L288.
Malenfant S, Brassard P, Paquette M, Le Blanc O, Chouinard A, Bonnet S, Provencher S. Continuous reduction in cerebral oxygenation during endurance exercise in patients with pulmonary arterial hypertension.. Physiol Rep 2020; 8(6):e14389.
Provencher S, Boucherat O, Berger RMF, Goumans MJ, Bonnet S. Reply to Chen et al.: BET Signaling: A Novel Therapeutic Target for Pulmonary Hypertension?. Am J Respir Crit Care Med 2020; 201(10):1313-1314.
Nickel NP, Yuan K, Dorfmuller P, Provencher S, Lai YC, Bonnet S, Austin ED, Koch CD, Morris A, Perros F, Montani D, Zamanian RT, de Jesus Perez VA. Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension.. Am J Respir Crit Care Med 2020; 201(2):148-157.
Ramirez FD, Jung RG, Motazedian P, Perry-Nguyen D, Di Santo P, MacDonald Z, Clancy AA, Labinaz A, Promislow S, Simard T, Provencher S, Bonnet S, Graham ID, Wells GA, Hibbert B. Journal Initiatives to Enhance Preclinical Research: Analyses of Stroke, Nature Medicine, Science Translational Medicine.. Stroke 2020; 51(1):291-299.
Klinke A, Schubert T, Müller M, Legchenko E, Zelt JGE, Shimauchi T, Napp LC, Rothman AMK, Bonnet S, Stewart DJ, Hansmann G, Rudolph V. Emerging therapies for right ventricular dysfunction and failure.. Cardiovasc Diagn Ther 2020; 10(5):1735-1767.
Veeroju S, Mamazhakypov A, Rai N, Kojonazarov B, Nadeau V, Breuils-Bonnet S, Li L, Weissmann N, Rohrbach S, Provencher S, Bonnet S, Seeger W, Schermuly R, Novoyatleva T. Effect of p53 activation on experimental right ventricular hypertrophy.. PLoS One 2020; 15(6):e0234872.
Maron BA, Gladwin MT, Bonnet S, De Jesus Perez V, Perman SM, Yu PB, Ichinose F. Perspectives on Cardiopulmonary Critical Care for Patients With COVID-19: From Members of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation.. J Am Heart Assoc 2020; 9(14):e017111.
Tian L, Wu D, Dasgupta A, Chen KH, Mewburn J, Potus F, Lima PDA, Hong Z, Zhao YY, Hindmarch CCT, Kutty S, Provencher S, Bonnet S, Sutendra G, Archer SL. Epigenetic Metabolic Reprogramming of Right Ventricular Fibroblasts in Pulmonary Arterial Hypertension: A Pyruvate Dehydrogenase Kinase-Dependent Shift in Mitochondrial Metabolism Promotes Right Ventricular Fibrosis.. Circ Res 2020; 126(12):1723-1745.
Sommer N, Ghofrani HA, Pak O, Bonnet S, Provencher S, Sitbon O, Rosenkranz S, Hoeper MM, Kiely DG. Current and future treatments of pulmonary arterial hypertension.. Br J Pharmacol 2021; 178(1):6-30.
Shimauchi T, Potus F, Bonnet S, Provencher S, Paulin R, Boucherat O.. Limitations and Flaws of Preclinical Pulmonary Hypertension Studies.. Adv Pulm Hypertens 2020; 19(2):47-54.
Negi V, Yang J, Speyer G, Pulgarin A, Handen A, Zhao J, Tai YY, Tang Y, Culley MK, Yu Q, Forsythe P, Gorelova A, Watson AM, Al Aaraj Y, Satoh T, Sharifi-Sanjani M, Rajaratnam A, Sembrat J, Provencher S, Yin X, Vargas SO, Rojas M, Bonnet S, Torrino S, Wagner NK, Schreiber SL, Dai M, Bertero T, Al Ghouleh I, Kim S, Chan SY.. Computational repurposing of therapeutic small molecules from cancer to pulmonary hypertension.. Sci Adv 2021; 7(43):eabh3794.
Habbout K, Omura J, Awada C, Bourgeois A, Grobs Y, Krishna V, Breuils-Bonnet S, Tremblay E, Mkannez G, Martineau S, Nadeau V, Roux-Dalvai F, Orcholski M, Jeyaseelan J, Gutstein D, Potus F, Provencher S, Bonnet S, Paulin R, Boucherat O. Implication of EZH2 in the Pro-Proliferative and Apoptosis-Resistant Phenotype of Pulmonary Artery Smooth Muscle Cells in PAH: A Transcriptomic and Proteomic Approach.. Int J Mol Sci 2021; 22(6):2957.
Grobs Y, Awada C, Lemay SE, Romanet C, Bourgeois A, Toro V, Nadeau V, Shimauchi K, Orcholski M, Breuils-Bonnet S, Tremblay E, Provencher S, Paulin R, Boucherat O, Bonnet S. Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension.. Int J Mol Sci 2021; 22(6):2919.
Malenfant S, Lebret M, Breton-Gagnon É, Potus F, Paulin R, Bonnet S, Provencher S. Exercise intolerance in pulmonary arterial hypertension: insight into central and peripheral pathophysiological mechanisms.. Eur Respir Rev 2021; 30(160):200284.
Mai V, Marceau-Ferron E, Bertoletti L, Lacasse Y, Bonnet S, Lega JC, Provencher S. Direct oral anticoagulants in the treatment of acute venous thromboembolism in patients with obesity: A systematic review with meta-analysis.. Pharmacol Res 2021; 163(0):105317.
Awada C, Grobs Y, Wu WH, Habbout K, Romanet C, Breuils-Bonnet S, Tremblay E, Martineau S, Paulin R, Bonnet S, Provencher S, Potus F, Boucherat O. (R)-Crizotinib Predisposes To and Exacerbates Pulmonary Arterial Hypertension in Animal Models.. Eur Respir J 2021; 57(5):2003271.
Lemay SE, Awada C, Shimauchi T, Wu WH, Bonnet S, Provencher S, Boucherat O. Fetal Gene Reactivation in Pulmonary Arterial Hypertension: GOOD, BAD, or BOTH?. Cells 2021; 10(6):1473.
Bonnet S, Gomez D. RNA Methylation: A New Regulator of Vascular Remodeling in Pulmonary Hypertension.. Am J Respir Crit Care Med 2021; 203(9):1060-1062.
Frump AL, Albrecht M, Yakubov B, Breuils-Bonnet S, Nadeau V, Tremblay E, Potus F, Omura J, Cook T, Fisher A, Rodriguez B, Brown RD, Stenmark KR, Rubinstein CD, Krentz K, Tabima DM, Li R, Sun X, Chesler NC, Provencher S, Bonnet S, Lahm T. 17?-Estradiol and estrogen receptor ? protect right ventricular function in pulmonary hypertension via BMPR2 and apelin.. J Clin Invest 2021; 131(6):e129433.
Dasgupta A, Chen KH, Lima PDA, Mewburn J, Wu D, Al-Qazazi R, Jones O, Tian L, Potus F, Bonnet S, Archer SL. PINK1-induced phosphorylation of mitofusin 2 at serine 442 causes its proteasomal degradation and promotes cell proliferation in lung cancer and pulmonary arterial hypertension.. FASEB J 2021; 35(8):e21771.
Jutras-Beaudoin N, Toro V, Lajoie AC, Breuils-Bonnet S, Paulin R, Potus F. Neutrophil-Lymphocyte Ratio as an Independent Predictor of Survival in Pulmonary Arterial Hypertension: An Exploratory Study.. CJC Open 2022; 4(4):357-363.
Provencher S, Potus F, Blais-Lecours P, Bernard S, Martineau S, Breuils-Bonnet S, Weatherald J, Sweeney M, Kulikowski E, Boucherat O, Bonnet S. BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Trial.. Am J Respir Crit Care Med 2022; 205(11):1357-1360.
Shimauchi T, Boucherat O, Yokokawa T, Grobs Y, Wu W, Orcholski M, Martineau S, Omura J, Tremblay E, Shimauchi K, Nadeau V, Breuils-Bonnet S, Paulin R, Potus F, Provencher S, Bonnet S. PARP1-PKM2 Axis Mediates Right Ventricular Failure Associated With Pulmonary Arterial Hypertension.. JACC Basic Transl Sci 2022; 7(4):384-403.
Chelladurai P, Kuenne C, Bourgeois A, Günther S, Valasarajan C, Cherian AV, Rottier RJ, Romanet C, Weigert A, Boucherat O, Eichstaedt CA, Ruppert C, Guenther A, Braun T, Looso M, Savai R, Seeger W, Bauer UM, Bonnet S, Pullamsetti SS. Epigenetic reactivation of transcriptional programs orchestrating fetal lung development in human pulmonary hypertension.. Sci Transl Med 2022; 14(648):eabe5407.
Al-Qazazi R, Lima PDA, Prisco SZ, Potus F, Dasgupta A, Chen KH, Tian L, Bentley RET, Mewburn J, Martin AY, Wu D, Jones O, Maurice DH, Bonnet S, Provencher S, Prins KW, Archer SL. Macrophage-NLRP3 Activation Promotes Right Ventricle Failure in Pulmonary Arterial Hypertension.. Am J Respir Crit Care Med 2022; 206(5):608-624.
Lemay SE, Bonnet S, Potus F. Commentary on: Xbp1s-Ddit3, DNA damage and pulmonary hypertension.. Clin Sci (Lond) 2022; 136(1):163-166.
Tremblay É, Gosselin C, Mai V, Lajoie AC, Kilo R, Weatherald J, Lacasse Y, Bonnet S, Lega JC, Provencher S. Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. Circulation 2022; 146(8):597-612.
Wu WH, Bonnet S, Shimauchi T, Toro V, Grobs Y, Romanet C, Bourgeois A, Vitry G, Omura J, Tremblay E, Nadeau V, Orcholski M, Breuils-Bonnet S, Martineau S, Ferraro P, Potus F, Paulin R, Provencher S, Boucherat O. Potential for inhibition of checkpoint kinases 1/2 in pulmonary fibrosis and secondary pulmonary hypertension.. Thorax 2022; 77(3):247-258.
Kudryashova TV, Dabral S, Nayakanti S, Ray A, Goncharov DA, Avolio T, Shen Y, Rode A, Pena A, Jiang L, Lin D, Baust J, Bachman TN, Graumann J, Ruppert C, Guenther A, Schmoranzer M, Grobs Y, Eve Lemay S, Tremblay E, Breuils-Bonnet S, Boucherat O, Mora AL, DeLisser H, Zhao J, Zhao Y, Bonnet S, Seeger W, Pullamsetti SS, Goncharova EA. Noncanonical HIPPO/MST Signaling via BUB3 and FOXO Drives Pulmonary Vascular Cell Growth and Survival.. Circ Res 2022; 130(5):760-778.
Bisserier M, Sun XQ, Fazal S, Turnbull IC, Bonnet S, Hadri L. Novel Insights into the Therapeutic Potential of Lung-Targeted Gene Transfer in the Most Common Respiratory Diseases.. Cells 2022; 11(6):984.
Lemay SE, Boucherat O, Bonnet S. Reverse Reaction of Nicotinamide Nucleotide Transhydrogenase Promotes ROS Production and Contributes to Right Ventricular Failure.. JACC Basic Transl Sci 2022; 7(7):678-680.
Bisserier M, Boucherat O, Bonnet S, Hadri L. Intra-Airway Gene Delivery for Pulmonary Hypertension in Rodent Models.. Methods Mol Biol 2022; 2573(0):263-278.
Zelt JGE, Cadete V, Deng Y, Godoy R, Cuillerier A, Rowe K, Abdul-Ghani M, Megeney L, Burelle Y, Giulivi A, Stewart AFR, Provencher S, Breuils-Bonnet S, Bonnet S, deKemp R, Beanlands R, Mielniczuk LM, Stewart DJ. Right Ventricular Maladaptation to Pressure Overload in Fischer Rats Is Associated With Profound Deficiency in Adenylate Kinase 1 and Impaired Ventricular Energetics.. Hypertension 2022; 79(12):2774-2786.
Boucherat O, Yokokawa T, Krishna V, Kalyana-Sundaram S, Martineau S, Breuils-Bonnet S, Azhar N, Bonilla F, Gutstein D, Potus F, Lawrie A, Jeyaseelan J, Provencher S, Bonnet S.. From heart to blood: LTBP-2 is a promising biomarker for pulmonary arterial hypertension.. Nat Cardiovasc Res 2022; 1(0):804-805.
Boucherat O, Agrawal V, Lawrie A, Bonnet S. The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure.. Circ Res 2022; 130(9):1466-1486.
Awada C, Bourgeois A, Lemay SE, Grobs Y, Yokokawa T, Breuils-Bonnet S, Martineau S, Krishna V, Potus F, Jeyaseelan J, Provencher S, Bonnet S, Boucherat O. G9a/GLP Targeting Ameliorates Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension.. Am J Respir Cell Mol Biol 2023; 68(5):537-550.
Yamamoto K, Lemay SE, Yokokawa T, Breuils-Bonnet S, Salem M, Potus F, Provencher S, Boucherat O, Bonnet S. DNA-Protein Kinase Catalytic Subunit as a Potential Target for Pulmonary Arterial Hypertension.. Am J Respir Cell Mol Biol 2023; 68(1):116-119.
Nayakanti SR, Friedrich A, Sarode P, Jafari L, Maroli G, Boehm M, Bourgeois A, Grobs Y, Khassafi F, Kuenne C, Guenther S, Dabral S, Wilhelm J, Weiss A, Wietelmann A, Kojonazarov B, Janssen W, de Man F, Provencher S, Khodr T, Seeger W, Bonnet S, Savai R, Schermuly RT, Pullamsetti SS.. Targeting Wnt-ß-Catenin-FOSL Signaling Ameliorates Right Ventricular Remodeling. Circ Res 2023; 132(11):1468-1485.
Mai V, Gosselin C, Tremblay É, Rompré G, Lajoie AC, Weatherald J, Lega JC, Bonnet S, Provencher S. Patients' perceptions on clinical trials outcomes in pulmonary arterial hypertension therapy.. Thorax 2023; 78(7):721-725.
Awada C, Boucherat O, Provencher S, Bonnet S, Potus F. The future of group 2 pulmonary hypertension: Exploring clinical trials and therapeutic targets.. Vascul Pharmacol 2023; 151(0):107180.

Dr Sébastien Bonnet

Domaine de recherche

Description des travaux

Prix et distinctions

Publications

Support tomorrow's medicine, now.